432 related articles for article (PubMed ID: 20014061)
1. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Varanese S; Howard J; Di Rocco A
Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
[No Abstract] [Full Text] [Related]
2. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
[No Abstract] [Full Text] [Related]
3. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
[TBL] [Abstract][Full Text] [Related]
4. [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure].
Lökk J
Lakartidningen; 2004 Jun; 101(23):2003-6. PubMed ID: 15232837
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
6. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Hanağasi HA; Kaptanoglu G; Sahin HA; Emre M
Mov Disord; 2000 Sep; 15(5):1016-7. PubMed ID: 11009218
[No Abstract] [Full Text] [Related]
7. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
[TBL] [Abstract][Full Text] [Related]
8. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
LeWitt PA
Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
[TBL] [Abstract][Full Text] [Related]
9. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Tousi B; Subramanian T
Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
[No Abstract] [Full Text] [Related]
10. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
11. Rating scales for dyskinesias in Parkinson's disease.
Goetz CG
Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
[No Abstract] [Full Text] [Related]
12. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Furukawa Y; Filiano JJ; Kish SJ
Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
[TBL] [Abstract][Full Text] [Related]
13. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
15. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
16. Ropinirole as compared with levodopa in Parkinson's disease.
Hiner BC; Earnhart M
N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
[No Abstract] [Full Text] [Related]
17. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
18. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Cheshire PA; Williams DR
J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
[TBL] [Abstract][Full Text] [Related]
19. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Bezard E; Brotchie JM; Gross CE
Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
